Moderna

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine targeting the Zaire strain responsible for the outbreak in the Democratic Republic of the Congo. The trial marks the first human testing of the candidate, which uses the same mRNA technology behind Moderna's COVID-19 vaccine. Coverage is highlighting the company's growing pipeline and the urgent need for new Ebola countermeasures in central Africa.

The updated 2026-2027 COVID-19 vaccine has become available, and people are booking appointments at pharmacies such as Walgreens, including Moderna boosters. The rollout comes as US trackers report a 13th COVID wave, with outbreaks in 40 states and territories and millions of estimated current infections, prompting renewed calls for annual boosters.